The impact of antimicrobial resistance on induction, transmission and treatment of Clostridium difficile infection

被引：3
|
作者：
Hong, Stacey [1 ,2 ]
Knight, Daniel R. [1 ]
Riley, Thomas, V [1 ,2 ,3 ,4 ]
机构：
[1] Murdoch Univ, Med Mol & Forens Sci, Murdoch, WA 6105, Australia
[2] Univ Western Australia, Queen Elizabeth II Med Ctr, Sch Biomed Sci, Nedlands, WA 6009, Australia
[3] Edith Cowan Univ, Sch Med & Hlth Sci, Joondalup, WA 6027, Australia
[4] Queen Elizabeth II Med Ctr, PathWest Lab Med, Dept Microbiol, Nedlands, WA 6009, Australia
来源：
MICROBIOLOGY AUSTRALIA | 2019年 / 40卷 / 02期
关键词：
METRONIDAZOLE RESISTANCE; MULTIDRUG-RESISTANCE; CLINICAL STRAINS; EPIDEMIOLOGY; HEALTH; GENE; FIDAXOMICIN; VANCOMYCIN;
D O I：
10.1071/MA19022
中图分类号：
Q93 [微生物学];
学科分类号：
071005 ; 100705 ;
摘要：
Clostridium difficile infection (CDI) of the gastrointestinal (GI) tract is a potentially life-threatening disease that has surpassed multi-drug-resistant Staphylococcus aureus as the commonest antimicrobial-resistant organism associated with healthcare(1). This obligate anaerobic spore-forming Gram-positive bacillus colonises the GI tract and its numbers increase after disruption of the commensal GI microbiota often induced by exposure to antimicrobial agents(2). Paradoxically, the disease that may follow its outgrowth necessitates further antimicrobial treatment. Already a major challenge to infection prevention and control strategies, there are indications that C. difficile is developing further resistance to currently used antimicrobial agents.
引用
收藏
页码：77 / 81
页数：5
相关论文
共 50 条
  • [1] Antimicrobial Resistance and Reduced Susceptibility in Clostridium difficile: Potential Consequences for Induction, Treatment, and Recurrence of C. difficile Infection
    Baines, Simon D.
    Wilcox, Mark H.
    ANTIBIOTICS-BASEL, 2015, 4 (03): : 267 - 298
  • [2] Antimicrobial resistance in Clostridium difficile
    Huang, Haihui
    Weintraub, Andrej
    Fang, Hong
    Nord, Carl Erik
    INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 2009, 34 (06) : 516 - 522
  • [3] Clostridium difficile Infection Antimicrobial Resistance Testing Reveals a High Metronidazole Resistance Rate
    Barkin, Jodie A.
    Fifadara, Nimita
    Barkin, Jamie S.
    GASTROENTEROLOGY, 2016, 150 (04) : S747 - S747
  • [4] Treatment of Clostridium difficile infection
    Wilcox, MH
    JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1998, 41 : 41 - 46
  • [5] Treatment of Clostridium difficile infection
    Stroehlein J.R.
    Current Treatment Options in Gastroenterology, 2004, 7 (3) : 235 - 239
  • [6] Treatment of Clostridium difficile infection
    Gerding, Dale N.
    Muto, Carlene A.
    Owens, Robert C., Jr.
    CLINICAL INFECTIOUS DISEASES, 2008, 46 : S32 - S42
  • [7] Ridinilazole: a novel antimicrobial for Clostridium difficile infection
    Cho, Jonathan C.
    Crotty, Matthew P.
    Pardo, Joe
    ANNALS OF GASTROENTEROLOGY, 2019, 32 (02): : 134 - 140
  • [8] Epidemic potential and antimicrobial resistance in Clostridium difficile
    Riley, Thomas V.
    MICROBIOLOGY AUSTRALIA, 2007, 28 (04) : 195 - 197
  • [9] Antimicrobial resistance in Clostridium difficile ribotype 017
    Imwattana, Korakrit
    Knight, Daniel R.
    Kullin, Brian
    Collins, Deirdre A.
    Putsathit, Papanin
    Kiratisin, Pattarachai
    Riley, Thomas, V
    EXPERT REVIEW OF ANTI-INFECTIVE THERAPY, 2020, 18 (01) : 17 - 25
  • [10] STUDIES ON THE RESISTANCE OF CLOSTRIDIUM DIFFICILE TO ANTIMICROBIAL AGENTS
    WUST, J
    HARDEGGER, U
    ZENTRALBLATT FUR BAKTERIOLOGIE MIKROBIOLOGIE UND HYGIENE SERIES A-MEDICAL MICROBIOLOGY INFECTIOUS DISEASES VIROLOGY PARASITOLOGY, 1988, 267 (03): : 383 - 394
12345